The DOI matches its Crossref record; 47 of the 49 references it cites were found in a registry or an index.
Patient-Specific iPSC-Derived Astrocytes Contribute to Non-Cell-Autonomous Neurodegeneration in Parkinson's Disease
Open accessAbstract
Parkinson's disease (PD) is associated with the degeneration of ventral midbrain dopaminergic neurons (vmDAns) and the accumulation of toxic α-synuclein. A non-cell-autonomous contribution, in particular of astrocytes, during PD pathogenesis has been suggested by observational studies, but remains to be experimentally tested. Here, we generated induced pluripotent stem cell-derived astrocytes and neurons from familial mutant LRRK2 G2019S PD patients and healthy individuals. Upon co-culture on top of PD astrocytes, control vmDAns displayed morphological signs of neurodegeneration and abnormal, astrocyte-derived α-synuclein accumulation. Conversely, control astrocytes partially prevented the appearance of disease-related phenotypes in PD vmDAns. We additionally identified dysfunctional chaperone-mediated autophagy (CMA), impaired macroautophagy, and progressive α-synuclein accumulation in PD astrocytes. Finally, chemical enhancement of CMA protected PD astrocytes and vmDAns via the clearance of α-synuclein accumulation. Our findings unveil a crucial non-cell-autonomous contribution of astrocytes during PD pathogenesis, and open the path to exploring novel therapeutic strategies aimed at blocking the pathogenic cross talk between neurons and glial cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in contrast to neuron-specific cell autonomous mechanisms that affect individual DA neurons within the SNc, non-cell autonomous mechanisms can cause dysfunction across the entire SNc, thereby leading to rapid DA neurodegeneration”
From Mitochondrial DNA Damage in Substantia Nigra Pars Compacta Astrocytes Exacerbates Dopaminergic Neuron Loss in a 6-Hydroxydopamine Mouse Model of Parkinsonism (2026) · cites this paper as di Domenico et al. 2019
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Interestingly, astrocytes generated from hiPSC derived from fibroblasts obtained from patients with CNS diseases (usually with a genetic mutation causative of disease or a risk polymorphism) show pathological phenotypes, including dysregulation of lipid metabolism11, alteration in the contents of the extracellular vesicles released by astrocytes80, reduced autophagy81, or altered STAT3 signaling82”
From Reactive astrocyte nomenclature, definitions, and future directions (2021) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., Charlson, F., Davis, A., Degenhardt, L., Dicker, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60692-4 · Cited by 6,414
Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009) · Nature Biotechnology · doi:10.1038/nbt.1529 · Cited by 3,620
Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024 · cited 2×
“…in a-syn turnover in these cells. a-syn has previously been shown to undergo degradation both by the ubiquitin/proteasome system and by autophagy (Cuervo et al., 2004; Webb et al., 2003); therefore a-syn flux in the presence of lysosomal and proteasome inhibitors (leupeptin and lactacystin,…”
BackgroundSelf-citationKriks, S., Shim, J., Piao, J., Ganat, Y. M., Wakeman, D. R., Xie, Z., Carrillo‐Reid, L., Auyeung, G., Antonacci, C. L., Buch, A., et al. (2011) · Nature · doi:10.1038/nature10648 · Cited by 1,951
α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300227200 · Cited by 1,429
Lee, H.-J., Suk, J.-E., Patrick, C., Bae, E.-J., Cho, J.-H., Rho, S., Hwang, D., Masliah, E., & Lee, S.-J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081125 · Cited by 877
α-Synuclein impairs macroautophagy: implications for Parkinson’s disease
Winslow, A. R., Chen, C.-W., Corrochano, S., Acevedo-Arozena, A., Gordon, D. E., Peden, A. A., Lichtenberg, M., Menzies, F. M., Ravikumar, B., Imarisio, S., et al. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201003122 · Cited by 825 · cited 2×
“Degradation of a-syn has been shown to occur by both proteasome and autophagic pathways, and conversely, high levels of a-syn have been demonstrated to be toxic for both systems (Tanaka et al., 2001; Webb et al., 2003; Winslow et al., 2010).”
BackgroundA common LRRK2 mutation in idiopathic Parkinson's disease
Gilks, W. P., Abou-Sleiman, P. M., Gandhi, S., Jain, S., Singleton, A., Lees, A. J., Shaw, K., Bhatia, K. P., Bonifati, V., Quinn, N. P., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17830-1 · Cited by 774
LRRK2 Mutant iPSC-Derived DA Neurons Demonstrate Increased Susceptibility to Oxidative Stress
Nguyen, H. N., Byers, B., Cord, B. J., Shcheglovitov, A., Byrne, J., Gujar, P., Kee, K., Schüle, B., Dolmetsch, R. E., Langston, J. W., et al. (2011) · Cell stem cell · doi:10.1016/j.stem.2011.01.013 · Cited by 768
A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity
Mussolino, C., Morbitzer, R., Lütge, F., Dannemann, N., Lahaye, T., & Cathomen, T. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr597 · Cited by 714
Flagged first, then by citations
2 of the 49 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 373
Astrocytes: The Stars in Neurodegeneration?
Dittlau, K. S., & Freude, K. (2024) · Biomolecules · doi:10.3390/biom14030289 · Cited by 39
(Re)building the nervous system: A review of neuron–glia interactions from development to disease
Demmings, M. D., Chagas, L. D. S., Traetta, M. E., Rodrigues, R. S., Acutain, M. F., Barykin, E. P., Datusalia, A. K., German‐Castelan, L., Mattera, V. S., Mazengenya, P., et al. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16258 · Cited by 44
Astrocytes in Neurodegeneration: Inspiration From Genetics
Huang, J., Li, C., & Shang, H. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.882316 · Cited by 40
The Contribution of Astrocyte Autophagy to Systemic Metabolism
Ortiz‐Rodriguez, A., & Arévalo, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072479 · Cited by 36
Glial cells in Parkinson´s disease: protective or deleterious?
Domingues, A. V., Pereira, I. M., Vilaça-Faria, H., Salgado, A. J., Rodrigues, A. J., & Teixeira, F. G. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03584-x · Cited by 38
Modelling Parkinson’s Disease: iPSCs towards Better Understanding of Human Pathology
Avazzadeh, S., Baena-Montes, J. M., Keighron, C. N., Sánchez, Y. F., & Quinlan, L. R. (2021) · Brain Sciences · doi:10.3390/brainsci11030373 · Cited by 38
The Mechanism and Function of Glia in Parkinson's Disease
Zhang, X., Zhang, R., Awan, M. U. N., & Bai, J. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.903469 · Cited by 38
LRRK2 at the pre‐synaptic site: A 16‐years perspective
Pischedda, F., & Piccoli, G. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15240 · Cited by 41
Jacquet, A. D. R., Denis, H. L., Cicchetti, F., & Alpaugh, M. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00999-7 · Cited by 36
Sheta, R., Teixeira, M., Idi, W., Pierre, M., Jacquet, A. D. R., Émond, V., Zorca, C. E., Vanderperre, B., Durcan, T. M., Fon, E. A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-22158-4 · Cited by 35
Advances and Applications of Brain Organoids
Li, Y., Zeng, P.-M., Wu, J., & Luo, Z. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01065-2 · Cited by 40
Parkinson's disease risk genes act in glia to control neuronal α-synuclein toxicity
Olsen, A. L., & Feany, M. Β. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105482 · Cited by 35
PET imaging of reactive astrocytes in neurological disorders
Liu, Y., Jiang, H., Qin, X., Tian, M., & Zhang, H. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05640-5 · Cited by 36
α‐Synuclein in Parkinson's Disease: From Bench to Bedside
Bellini, G., D’Antongiovanni, V., Palermo, G., Antonioli, L., Fornai, M., Ceravolo, R., Bernardini, N., Derkinderen, P., & Pellegrini, C. (2024) · Medicinal Research Reviews · doi:10.1002/med.22091 · Cited by 42
Jayaramayya, K., Iyer, M., Venkatesan, D., Balasubramanian, V., Narayanasamy, A., Subramaniam, M. D., Cho, S., & Vellingiri, B. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.02.001 · Cited by 34
Bai, Y., Su, X., Piao, L., Jin, Z., & Jin, R. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.556215 · Cited by 34
Novel Approaches Used to Examine and Control Neurogenesis in Parkinson′s Disease
Salmina, A. B., Рафаилевна, К. М., Vetchinova, A. S., & Illarioshkin, S. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179608 · Cited by 38
Preparation and Co‐Culture of iPSC‐Derived Dopaminergic Neurons and Astrocytes
Jacquet, A. D. R. (2019) · Current Protocols in Cell Biology · doi:10.1002/cpcb.98 · Cited by 34
Harcha, P. A., Garcés, P., Arredondo, C., Fernández, G. R., Sáez, J. C., & van Zundert, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041924 · Cited by 38
Astrocyte-to-neuron reprogramming and crosstalk in the treatment of Parkinson's disease
Wang, Y., Xia, Y. F., Kou, L., Yin, S., Chi, X., Li, J., Sun, Y., Wu, J., Zhou, Q., Zou, W., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106224 · Cited by 33
Carola, G., Malagarriga, D., Calatayud, C., Pons‐Espinal, M., Blasco-Agell, L., Richaud‐Patín, Y., Fernández‐Carasa, I., Baruffi, V., Beltramone, S., Molina, E., et al. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00198-3 · Cited by 31
Self-citationNeuronal Cultures: Exploring Biophysics, Complex Systems, and Medicine in a Dish
Soriano, J. (2023) · Biophysica · doi:10.3390/biophysica3010012 · Cited by 33
Self-citationLiu, M., Liu, S., Lin, Z.-H., Chen, X., Jiao, Q., Du, X., & Jiang, H. F. (2025) · Biomolecules · doi:10.3390/biom15010149 · Cited by 32
Autophagy in the Immunosuppressive Perivascular Microenvironment of Glioblastoma
Molina, M. L., García‐Bernal, D., Martı́nez, S., & Valdor, R. (2019) · Cancers · doi:10.3390/cancers12010102 · Cited by 30
Liang, X., Cao, S., Xie, P., Hu, X., Lin, Y., Liang, J., Zhang, S., Xian, B., Cao, H., Luan, T., et al. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c00196 · Cited by 30
Labau, J. I. R., Anđelić, M., Faber, C. G., Waxman, S. G., Lauria, G., & Dib‐Hajj, S. D. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114223 · Cited by 32
Astrocytes expressing Vitamin D‐activating enzyme identify Parkinson’s disease
Mazzetti, S., Barichella, M., Giampietro, F., Giana, A., Calogero, A. M., Amadeo, A., Palazzi, N., Comincini, A., Giaccone, G., Bramerio, M., et al. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13801 · Cited by 28
Using induced pluripotent stem cells for modeling Parkinson’s disease
Ke, M., Chong, C., & Su, H. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i9.634 · Cited by 31
Modeling Cell-Cell Interactions in Parkinson’s Disease Using Human Stem Cell-Based Models
Simmnacher, K., Lanfer, J., Rizo, T., Kaindl, J., & Winner, B. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00571 · Cited by 32
Kouroupi, G., Antoniou, N., Prodromidou, K., Taoufik, E., & Matsas, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197113 · Cited by 30
MacDougall, G., Brown, L. Y., Kantor, B., & Chiba‐Falek, O. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.01.001 · Cited by 31
Ganglioside GM1 Targets Astrocytes to Stimulate Cerebral Energy Metabolism
Finsterwald, C., Dias, S., Magistretti, P. J., & Lengacher, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.653842 · Cited by 30
ncRNAs and their impact on dopaminergic neurons: Autophagy pathways in Parkinson's disease
Thapa, R., Moglad, E. H. O., Afzal, M., Gupta, G., Bhat, A. A., Almalki, W. H., Kazmi, I. A., Alzarea, S. I., Pant, K., Ali, H., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102327 · Cited by 29
Lendemeijer, B., Unkel, M., Smeenk, H., Mossink, B., Hijazi, S., Gordillo-Sampedro, S., Shpak, G., Slump, D. E., van den Hout, M. C. G. N., van IJcken, W. F. J., et al. (2024) · eNeuro · doi:10.1523/eneuro.0148-24.2024 · Cited by 31
Barnett, D., Bohmbach, K., Grelot, V., Charlet, A., Dallérac, G. M., Ju, Y. H., Nagai, J., & Orr, A. G. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.1376-23.2023 · Cited by 27
An Overview of Epigenetic Changes in the Parkinson’s Disease Brain
Klokkaris, A., & Migdalska‐Richards, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116168 · Cited by 31
Interrogating Parkinson's disease associated redox targets: Potential application of CRISPR editing
Artyukhova, M. A., Tyurina, Y. Y., Chu, C. T., Zharikova, T. M., Bayır, H., Kagan, V. E., & Timashev, P. S. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.06.007 · Cited by 26
Leucine‐rich repeat kinase 2 and lysosomal dyshomeostasis in Parkinson disease
Cogo, S., Manzoni, C., Lewis, P. A., & Greggio, E. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14908 · Cited by 27
Autophagy and Redox Homeostasis in Parkinson’s: A Crucial Balancing Act
Jiménez-Moreno, N., & Lane, J. D. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/8865611 · Cited by 26
Synaptic proteostasis in Parkinson's disease
Nachman, E., & Verstreken, P. (2021) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2021.09.001 · Cited by 27
Zhang, Z., Zhang, X., Wu, X., Zhang, Y., Lu, J., & Li, D. (2022) · Cerebral Cortex · doi:10.1093/cercor/bhac007 · Cited by 27
A Focus on Astrocyte Contribution to Parkinson’s Disease Etiology
Prunell, G., & Olivera‐Bravo, S. (2022) · Biomolecules · doi:10.3390/biom12121745 · Cited by 27
Modeling Neurological Disorders with Human Pluripotent Stem Cell-Derived Astrocytes
Suga, M., Kondo, T., & Inoue, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163862 · Cited by 27
Rajpurohit, C. S., Kumar, V., Cheffer, A., Oliveira, D., Ulrich, H., Okamoto, O. K., Zatz, M., Ansari, U. A., Khanna, V. K., & Pant, A. B. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02006-0 · Cited by 25
Grochowska, M. M., Mascaro, A. C., Boumeester, V., Natale, D., Breedveld, G. J., Geut, H., van Cappellen, W. A., Boon, A. J. W., Kievit, A. J. A., Sammler, E. M., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02313-3 · Cited by 22
Autophagy in neural stem cells and glia for brain health and diseases
Nagayach, A., & Wang, C. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.382227 · Cited by 30
Vicente-Acosta, A., Giménez-Cassina, A., Díaz‐Nido, J., & Loría, F. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02442-w · Cited by 19
Defective proteostasis in induced pluripotent stem cell models of frontotemporal lobar degeneration
Mahali, S., Martinez, R., King, M., Verbeck, A., Harari, O., Benitez, B. A., Horie, K., Sato, C., Temple, S., & Karch, C. M. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02274-5 · Cited by 33
When glia meet induced pluripotent stem cells (iPSCs)
Li, L., & Shi, Y. (2020) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2020.103565 · Cited by 24
Molecular Pathways Involved in LRRK2-Linked Parkinson’s Disease: A Systematic Review
Ravinther, A. I., Dewadas, H. D., Tong, S. R., Foo, C. N., Lin, Y., Chien, C., & Lim, Y. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911744 · Cited by 24
Inborn errors of metabolism: Lessons from iPSC models
Escribá, R., Ferrer‐Lorente, R., & Raya, Á. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09671-z · Cited by 22
LRRK2 signaling in neurodegeneration: two decades of progress
Iannotta, L., & Greggio, E. (2021) · Essays in Biochemistry · doi:10.1042/ebc20210013 · Cited by 19
The multifaceted role of LRRK2 in Parkinson's disease: From human iPSC to organoids
Oun, A., Sabogal-Guáqueta, A. M., Galuh, S., Alexander, A., Kortholt, A., & Dolga, A. M. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105837 · Cited by 23
Joshi, R., Missong, H., Mishra, J., Kaur, S., Saini, S., Kandimalla, R. J. L., Reddy, P. H., Babu, A. M., Bhatti, G. K., & Bhatti, J. S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105067 · Cited by 23
Weiss, F. C., Hughes, L. P., Fu, Y., Bardy, C., Halliday, G. M., & Dzamko, N. L. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00448-3 · Cited by 25
Seranova, E., Palhegyi, A. M., Verma, S., Dimova, S., Lasry, R., Naama, M., Sun, C., Barrett, T. G., Rosenstock, T. R., Kumar, D., et al. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.01.024 · Cited by 20
Chaperone-Mediated Autophagy after Spinal Cord Injury
Handa, K., Kanno, H., Matsuda, M., Sugaya, T., Murakami, T., Prudnikova, M., Ozawa, H., & Itoi, E. (2020) · Journal of Neurotrauma · doi:10.1089/neu.2019.6820 · Cited by 22
Ferrer‐Lorente, R., Lozano‐Cruz, T., Fernández‐Carasa, I., Miłowska, K., de la Mata, F. J., Bryszewska, M. J., Consiglio, A., Ortega, P., Gómez, R., & Raya, Á. (2021) · Biomacromolecules · doi:10.1021/acs.biomac.1c00884 · Cited by 22
Self-citationUnderstanding the Potential of Genome Editing in Parkinson’s Disease
Arango, D., Bittar, A., Esmeral, N. P., Ocasión, C., Muñoz-Camargo, C., Cruz, J. C., Reyes, L. H., & Bloch, N. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179241 · Cited by 24
Cell reprogramming therapy for Parkinson’s disease
Dong, W., Liu, S., Li, S., & Wang, Z. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.390965 · Cited by 21
Non-Cell-Autonomous Neurotoxicity in Parkinson’s Disease Mediated by Astroglial α-Synuclein
Chai, M., & Kohyama, J. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.01.011 · Cited by 19
The Role of Astrocytes and Alpha-Synuclein in Parkinson’s Disease: A Review
Brash-Arias, D., García, L. I., Pérez-Estudillo, C. A., Rojas-Durán, F., Aranda-Abreu, G. E., Herrera‐Covarrubias, D., & Chi-Castañeda, D. (2024) · NeuroSci · doi:10.3390/neurosci5010005 · Cited by 20
Solana‐Manrique, C., Sánchez‐Pérez, A. M., Paricio, N., & Muñoz‐Descalzo, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020620 · Cited by 21
Pons-Espinal, M., Blasco-Agell, L., & Consiglio, A. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03700-x · Cited by 18
Self-citationFu, H., Cui, Y., Li, Q., Wang, D., Li, H., Yang, L., Wang, D., & Zhou, J. (2022) · Brain Pathology · doi:10.1111/bpa.13114 · Cited by 18
Rademacher, D. J. (2023) · Biomedicines · doi:10.3390/biomedicines11041187 · Cited by 18
Banerjee, R., Raj, A., Potdar, C., Pal, P. K., Yadav, R., Kamble, N. L., Holla, V. V., & Datta, I. (2023) · Cells · doi:10.3390/cells12121592 · Cited by 18
Supakul, S., Murakami, R., Oyama, C., Shindo, T., Hatakeyama, Y., Itsuno, M., Bannai, H., Shibata, S., Maeda, S., & Okano, H. (2024) · Inflammation and Regeneration · doi:10.1186/s41232-023-00310-5 · Cited by 20
Astrocytes in Parkinson's disease: from preclinical assays to in vivo imaging and therapeutic probes
Zeng, Z., Roussakis, A., Lao–Kaim, N. P., & Piccini, P. P. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.07.012 · Cited by 19
Autophagy in alzheimer disease pathogenesis and its therapeutic values
Angst, G., Jia, N., Esqueda, L. T., Fan, Y., Cai, Q., & Wang, C. (2025) · Autophagy Reports · doi:10.1080/27694127.2025.2471677 · Cited by 22
Insights into Human-Induced Pluripotent Stem Cell-Derived Astrocytes in Neurodegenerative Disorders
Kumar, M., Nguyen, T. P. N., Milanese, M., & Bonanno, G. (2022) · Biomolecules · doi:10.3390/biom12030344 · Cited by 20
Wu, J., Xu, W., Su, Y., Wang, G., & Ma, J. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01416-3 · Cited by 21
Blasco-Agell, L., Pons‐Espinal, M., Testa, V., Roch, G., Montero-Muñoz, J., Fernández‐Carasa, I., Baruffi, V., González-Sepúlveda, M., Richaud‐Patín, Y., Jiménez‐Delgado, S., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08544-4 · Cited by 16
Self-citationTherapeutic approaches to cholinergic deficiency in Lewy body diseases
Barrett, M. J., Cloud, L. J., Shah, H. P., & Holloway, K. L. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1676152 · Cited by 16
Bhargava, A., Sandoval-Castellanos, A. M., Shah, S. S., & Ning, K. (2022) · Interface Focus · doi:10.1098/rsfs.2022.0040 · Cited by 15
Yeap, Y. J., Tng, T. J. W., Lee, M. J., Goh, M., & Lim, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032523 · Cited by 18
Mohammed, O. A., Elballal, M. S., El-Husseiny, A. A., Khidr, E. G., Tabaa, M. M. E., Elazazy, O. E., Abd‐Elmawla, M. A., Elesawy, A. E., Ibrahim, H. M., Abulsoud, A. I., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.155023 · Cited by 16
Astrocytes Drive Divergent Metabolic Gene Expression in Humans and Chimpanzees
Zintel, T. M., Pizzollo, J., Claypool, C. G., & Babbitt, C. C. (2023) · Genome Biology and Evolution · doi:10.1093/gbe/evad239 · Cited by 18
Zalon, A. J., Quiriconi, D. J., Pitcairn, C., & Mazzulli, J. R. (2024) · The Neuroscientist · doi:10.1177/10738584241232963 · Cited by 16
What we can learn from iPSC-derived cellular models of Parkinson's disease
Caiazza, M. C., Lang, C., & Wade‐Martins, R. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.11.002 · Cited by 15
Poly (ADP-ribose) polymerase 1 and Parkinson's disease: A study in post-mortem human brain
Salemi, M., Mazzetti, S., Leonardis, M. D., Giampietro, F., Medici, V., Poloni, T. E., Cannarella, R., Giaccone, G., Pezzoli, G., Cappelletti, G., et al. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.104978 · Cited by 16
Lee, J. H., Han, J., Joe, E.-H., & Jou, I. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00747-1 · Cited by 17
Albert, K., Kälvälä, S., Hakosalo, V., Syvänen, V., Krupa, P., Niskanen, J., Peltonen, S., Sonninen, T.-M., & Lehtonen, Š. (2022) · Biomedicines · doi:10.3390/biomedicines10102649 · Cited by 16
Vitamin D3 actions on astrocyte cells: A target for therapeutic strategy in Parkinson’s disease?
de Siqueira, E. A., Magalhães, E. P., de Menezes, R. R. P. P. B., Sampaio, T. L., Lima, D. B., Martins, C. D. S., Neves, K. R. T., Brito, G. A. D. C., Martins, A. M. C., & Viana, G. S. D. B. (2022) · Neuroscience Letters · doi:10.1016/j.neulet.2022.136997 · Cited by 16
Heat Shock Protein 90 in Parkinson’s Disease: Profile of a Serial Killer
Mansour, H. M., Mohamed, A. F., Khattab, M. M., & El-Khatib, A. S. (2023) · Neuroscience · doi:10.1016/j.neuroscience.2023.11.031 · Cited by 15
How Parkinson’s Disease-Linked LRRK2 Mutations Affect Different CNS Cell Types
Bailey, H. M., & Cookson, M. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230432 · Cited by 18
Canonical and noncanonical autophagy: involvement in Parkinson’s disease
Sakurai, M., & Kuwahara, T. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1518991 · Cited by 16
Towards physiologically relevant human pluripotent stem cell (hPSC) models of Parkinson’s disease
Coccia, E., & Ahfeldt, T. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02326-5 · Cited by 16
Zhang, M., Li, C., Ren, J., Wang, H., Fang, Y., Wu, J., & Tang, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.909303 · Cited by 16
Crompton, L., McComish, S. F., Stathakos, P., Llana, O. C., Lane, J. D., & Caldwell, M. A. (2021) · Journal of Visualized Experiments · doi:10.3791/62095 · Cited by 14
Autophagy and Glycative Stress: A Bittersweet Relationship in Neurodegeneration
Gómez, O., Perini-Villanueva, G., Yuste, A., Rodríguez‐Navarro, J. A., Poch, E., & Bejarano, E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.790479 · Cited by 14
McComish, S. F., Copas, A. N. M., & Caldwell, M. A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.851058 · Cited by 17
Is Glial Dysfunction the Key Pathogenesis of LRRK2-Linked Parkinson’s Disease?
Iseki, T., Imai, Y., & Hattori, N. (2023) · Biomolecules · doi:10.3390/biom13010178 · Cited by 14
Metabolic and immune dysfunction of glia in neurodegenerative disorders: Focus on iPSC models
Rõlova, T., Lehtonen, Š., Goldsteins, G., Kettunen, P., & Koıstınaho, J. (2020) · Stem Cells · doi:10.1002/stem.3309 · Cited by 14
LRRK2 Kinase Inhibition Attenuates Astrocytic Activation in Response to Amyloid β1-42 Fibrils
Filippini, A., Salvi, V., Dattilo, V., Magri, C., Castrezzati, S., Veerhuis, R., Bosisio, D., Gennarelli, M., & Russo, I. (2023) · Biomolecules · doi:10.3390/biom13020307 · Cited by 13
Zheng, Y. F., Lu, P., Jiang, G., Zhou, J., Yang, S., Bai, L., Li, X., & He, M. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114986 · Cited by 14
Oh, Y. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.6.142 · Cited by 13
Pinheiro, P. D. S. M., Diniz, L. P., Franco, L. S., Siqueira, M., & Gomes, F. C. A. (2025) · Pharmaceuticals · doi:10.3390/ph18101471 · Cited by 13
Walecha, V., & Luthra, P. M. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04559-9 · Cited by 12
Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells
Goveas, L. M., Mutez, E., Chartier‐Harlin, M., & Taymans, J. (2021) · Cells · doi:10.3390/cells10050981 · Cited by 14
Metadata
- Authors
- di Domenico, A., Carola, G., Calatayud, C., Pons-Espinal, M., Muñoz, J. P., Richaud-Patin, Y., Fernandez-Carasa, I., Gut, M., Faella, A., Parameswaran, J., Soriano, J., Ferrer, I., Tolosa, E., Zorzano, A., Cuervo, A. M., Raya, A., & Consiglio, A.
- Affiliations
- Bellvitge University Hospital (ES)
- Institute for Research in Biomedicine (ES)
- Centro Nacional de Análisis Genómico (ES)
- Universitat de Barcelona (ES)
- Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
- Corresponding author
- Consiglio, Antonella
- ORCID
- Venue
- Stem Cell Reports
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 12
- Issue
- 2
- Pages
- 213-229
- ISSN
- 2213-6711 (ISSN-L)
- PMC
- PMC6372974
- OpenAlex
- W2911036111
- Cited by
- 372
- References
- 49
- Citations by year
- 2026: 32 · 2025: 38 · 2024: 44 · 2023: 45 · 2022: 65 · 2021: 69 · 2020: 53 · 2019: 26
- FWCI
- 36.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Stem Cell Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Repositori digital de la UPF (Universitat Pompeu Fabra) (submittedVersion, cc-by)
- Funders
- Agència de Gestió d'Ajuts Universitaris i de Recerca (2014-SGR-878, 2017-SGR-899)
- Ministerio de Educación, Cultura y Deporte (BES-2014-069603, FPU12/03332)
- Ministerio de Economía y Competitividad (BFU2016-80870-P, FIS2016-78507-C2-2-P, SAF2015-69706-R)
- Instituto de Salud Carlos III
- European Regional Development Fund (RD16/0011/0024)
- Generalitat de Catalunya
- European Research Council (2012-StG-311736-PD-HUMMODEL)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Parkinson's disease, astrocytes, non-cell autonomous neurodegeneration, induced pluripotent stem cell-derived astrocytes, dopaminergic neurons, ventral midbrain, LRRK2 G2019S, familial Parkinson's disease, alpha-synuclein accumulation, chaperone-mediated autophagy, macroautophagy, neuron-glia interactions
- MeSH terms
- Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Astrocytes, Autophagy, Cell Differentiation, Cells, Cultured, Humans, Mesencephalon, Neuroglia, Parkinson Disease, Phenotype, Coculture Techniques, alpha-Synuclein, Induced Pluripotent Stem Cells, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
